Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons

INTRODUCTION: Over the past 15 years, the discovery and development of oral medications that selectively inhibit the enzyme phosphodiesterase type 5 (PDE5) have revolutionised the treatment of erectile dysfunction (ED). Currently, three PDE5 inhibitors are widely available clinically, i.e., sildenaf...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferguson, James E., Carson, Culley C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443003/
https://www.ncbi.nlm.nih.gov/pubmed/26558086
http://dx.doi.org/10.1016/j.aju.2013.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443003/
https://www.ncbi.nlm.nih.gov/pubmed/26558086
http://dx.doi.org/10.1016/j.aju.2013.07.009

Ejemplares similares